Eli Lilly Price Forecast: The Next Big Stock After Weight-Loss Drug Breakthrough?

Eli Lilly is one of the most popular names today in America's weight-loss and diabetes drug market. Its drugs delivered an average weight loss of 28.3% in a Phase 3 trial, approaching results historically associated with bariatric surgery and potentially giving Lilly another major product after the success of Mounjaro.

The company's stock price has benefited from this hype, gaining almost 9% in August. With Eli Lilly already valued at roughly $1.1 trillion and management recently raising its 2026 revenue guidance, investors are increasingly focused on whether future drug launches can support the premium valuation.

Here's the latest Eli Lilly price prediction from CoinCodex analysts.

Retatrutide Could Become Eli Lilly's Next Major Obesity Drug

Retatrutide is emerging as one of the most important products in Eli Lilly's development pipeline. In the Phase 3 TRIUMPH-1 study, participants taking the drug lost an average of 28.3% of their body weight after 80 weeks.

… Continue reading the full article at the original source below.